How to access Retevmo from Bahrain, the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
A Bahraini patient diagnosed with a RET-altered cancer, most commonly RET-fusion non-small-cell lung cancer (NSCLC) or RET-mutant medullary thyroid cancer, may receive a prescription for Retevmo (selpercatinib) from their treating oncologist after molecular testing confirms the alteration. Retevmo is FDA-approved in the United States and is the leading selective RET inhibitor with activity across multiple RET-altered cancer types. In Bahrain, Retevmo may not yet be routinely stocked in hospital pharmacies because of the relatively low incidence of RET-altered disease, which is why your oncologist may be coordinating a named-patient import pathway on your behalf.
This guide explains the legal pathway, what documentation your physician needs, typical timing and cost bands, and where Reserve Meds fits in.
The clinical situation
Retevmo is a selective oral RET kinase inhibitor with activity in both RET-fusion cancers (NSCLC, thyroid) and RET-mutant medullary thyroid cancer. Eligibility requires molecular confirmation of the RET alteration. The manufacturer is Eli Lilly. Dosing is typically 160 mg orally twice daily (weight-based at lower weights), with monitoring for hypertension, QTc prolongation, liver enzymes, haemorrhage, and allergic reactions. Your oncologist will confirm the alteration and sequencing against your overall treatment plan.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Is Retevmo legally importable into Bahrain?
Yes, through the National Health Regulatory Authority (NHRA) named-patient import framework, administered via the administering hospital's importing pharmacy and the NHRA Pharmacy and Drug Control Department. Bahrain has a mature named-patient mechanism that supports cross-border access to specialised oncology products.
The framework rests on four anchors: (a) the medicine is approved by a recognised reference authority (FDA qualifies), (b) no clinically equivalent locally registered alternative is suitable for the patient, (c) the treating physician takes clinical responsibility for use, and (d) the importing party documents chain of custody from the US source to the administering facility. Applications are typically filed by the tertiary centre's importing pharmacy on the physician's behalf.
How the pathway works, step by step
- Consultation with your treating oncologist. The decision to prescribe Retevmo is a clinical one, based on RET alteration status and treatment line. Your oncologist documents the rationale.
- Administering facility identification. A Bahraini tertiary oncology centre with an importing pharmacy files on behalf of the physician.
- NHRA named-patient application. Your physician or the hospital's importing pharmacy files an application with NHRA including clinical rationale, patient identifier, product details, and chain-of-custody plan.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure product from the manufacturer's authorised distribution chain under DSCSA.
- Temperature-controlled shipment. Retevmo is a stable oral capsule; shipments travel with tamper-evident packaging and end-to-end documentation.
- Arrival and dispensing support. Your oncologist remains the treating clinician. Reserve Meds coordinates re-supply ahead of cycle end to avoid treatment gaps.
What documentation your physician needs
Your physician will typically need to provide:
- A clinical rationale letter confirming the RET alteration, tumour type, prior therapies, and Retevmo as the indicated treatment
- Verification of their Bahrain medical licence (NHRA / QCHP)
- A current prescription naming the product, strength, and quantity
- Patient identifier (anonymised reference preferred)
- The planned treatment cadence (continuous daily therapy with monthly re-supply)
Reserve Meds provides a physician documentation kit that bundles the templates NHRA reviewers expect to see for oncology oral therapies under named-patient import.
Costs and timing
Retevmo's US cash-pay drug-only reference price for a 30-day supply sits in an indicative 2026 drug-only range (delivered quote issued at intake) of roughly USD 21,000-24,000. Logistics, NHRA documentation handling, and concierge coordination add incremental cost; Reserve Meds issues a full transparent quote at the start of intake.
Indicative timing for first shipment arrival after cohort intake opens is 7-14 days from the moment a complete NHRA application is submitted. Subsequent re-supply cycles are generally faster once the pathway is established.
If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.
Reserve Meds's role
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Retevmo specifically, we provide:
- Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
- Documentation. Regulatory documentation package for your physician and for NHRA review.
- Logistics. Temperature-stable shipment and chain-of-custody coordination.
- Concierge case lead. A named point of contact for your family and your physician throughout the process.
What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating oncologist.
Frequently asked
Is this legal in Bahrain? Yes, when executed through the NHRA named-patient framework with appropriate documentation. The pathway has been used routinely across oncology for many years. See our trust and compliance page.
Is RET testing reliable? RET fusion testing is typically performed by next-generation sequencing of tumour tissue or plasma. Your oncologist will confirm the lab and method used for your report.
What if my oncologist has not done this before? Named-patient import is an institutional process your oncologist's hospital will have encountered. Our documentation kit closes the gap for first-time applicants.
Will private insurance cover this? Cash-pay is the default. Some Bahraini private insurers reimburse named-patient imports on case-by-case approval; we supply documentation for your submission but do not process insurance claims directly.
Next step
For Retevmo coordination in Bahrain, start your case at the portal or message us on WhatsApp. Our concierge case lead will respond within 24 hours.
Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Clinical & regulatory review: Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last medically reviewed: 2026-04-23.